Antepartum Fetal Surveillance

Navigation menu

Topic Index
Clin Infect Dis ;44 7: Association between implementation of a medical team training program and surgical morbidity. Kindly advise me on how to calculate a sample size for my study. J Hosp Infect ;52 3: Principles of the environmental risk assessment, ERA: Middle cerebral artery flow velocity waveforms in normal and small-for-gestational-age fetuses. Farquhar Prepares international and U.

Infection and transmission

Code of Practice for the Care and Handling of Hatching Eggs, Breeders, Chicken and Turkeys

Research into the role of lifestyle factors such as smoking, chewing tobacco, alcohol consumption, parity, diet, sunbathing, and exercise in the origin and cause of cancer or increasing the risk of cancer Research into the social determinants of cancer such as crime, housing dilapidation poor housing , neighbourhood level socioeconomic status and services and their relationship to cancer incidence and mortality etc.

Viral oncogenes and viral regulatory genes associated with cancer causation Contextual factors contributing to cancer incidence e. Investigating a role for stem cells in the etiology of tumours 2. Informatics and informatics networks; for example, patient databanks Specimen resources serum, tissue, etc. If it is only a tool or a methodology, code to the research instead.

This does not include longer term research based training, such as Ph. Back to Top Prevention Research included in this category looks at identifying individual and population-based primary prevention interventions, which reduce cancer risk by reducing exposure to cancer risks and increasing protective factors.

Research on determinants of personal behaviors, such as physical activity, sun exposure, alcohol and tobacco use, known to affect cancer risk and interventions including educational and behavioral interventions, such as e-cigarettes, directed at individuals as well as population-based interventions including social marketing campaigns, environmental supports, and regulatory, policy and legislative changes to change determinants or to target health inequalities.

Directed education to specified populations of patients, health care providers, and at-risk groups about cancer risk and prevention and relevant interventions with the intent of promoting increased awareness and behavioural change. Chemopreventive agents and their discovery, mechanism of action, development, testing in model systems, and clinical testing Other non-vaccine preventive measures such as prophylactic surgery e.

Vaccines for prevention, their discovery, mechanism of action, development, testing in model systems, and clinical testing e. Discovery or identification and characterization of markers e. Development, refinement, and preliminary evaluation e. Preliminary evaluation with respect to laboratory sensitivity, laboratory specificity, reproducibility, and accuracy Research into mechanisms assessing tumor response to therapy at a molecular or cellular level 4.

Includes education, communication e. Research into improvements in techniques to assess clinical response to therapy 4. Informatics and informatics networks; for example, patient databanks Specimen resources serum, tissue, images, etc.

Research into the development of localized therapies to prevent recurrence Identifying mechanisms of action of existing localized therapies and targets, including cancer stem cells.

Clinical testing and application of therapies with a component administered systemically but that act locally e. Phase I, II, or III clinical trials of promising therapies that are administered locally Side effects, toxicity, and pharmacodynamics Clinical testing of localized therapies to prevent recurrence and prevent and treat metastases 5. Phase I, II, or III clinical trials of promising therapies administered systemically Side effects, toxicity, and pharmacodynamics Clinical testing of systemic therapies to prevent recurrence and prevent and treat metastases 5.

Development and testing of combined local and systemic approaches to treatment e. Informatics and informatics networks; for example, clinical trials networks and databanks Mathematical and computer simulations Specimen resources serum, tissue, etc.

Prevention and management of long-term treatment-related toxicities and sequelae, including symptom management e.

Biopsy performed on the same lesion as EMR is not separately reportable. This code includes endoscopic ultrasound EUS of the esophagus, stomach, and either the duodenum or a surgically-altered stomach where the jejunum is examined distal to the anastomosis. The new code includes pre- and post-dilation and guide wire passage when performed. Separate reporting of pre- or post-dilation or guide wire passage when performing ablation of the same lesion during the same session would not be appropriate.

Ablation procedures are reported without a reduced services modifier 52, even if all three components pre-dilation, post-dilation or guide wire passage are not performed during the same session.

Code , EGD with placement of stent is reported without a reduced services modifier 52, even if all three components pre-dilation, post-dilation, and guide wire passage are not performed during the same session. Separate reporting of pre-dilation, post-dilation or guide wire passage of the same lesion during the same session would not be appropriate.

Is there a difference regarding the use of modifiers 52 and 53 with regards to upper and lower endoscopic procedures?

To report esophagogastroscopy where the duodenum is deliberately not examined e. EGD is performed and a tube is placed into the stomach. The duodenum is not examined and there is no plan to perform repeat EGD to examine the duodenum.

Report procedure with modifier EGD is performed for evaluation of GI bleeding; the stomach is full of blood and the duodenum is not examined. Plan to control bleeding, lavage stomach and repeat upper endoscopy. Limitations Colonoscopy is generally not covered for treating the following: Coverage Limitations for EGD s Distress that is chronic, non-progressive, atypical for known organic disease and is considered functional in origin there are occasional exceptions in which an endoscopic examination may be done once to rule out organic disease, especially if symptoms are unresponsive to therapy.

Uncomplicated heartburn responding to medical therapy. Metastatic adenocarcinoma of unknown primary site when the results will not alter management. Asymptomatic or uncomplicated sliding hiatus hernia. Uncomplicated duodenal bulb ulcer that has responded to therapy. Deformed duodenal bulb when symptoms are absent or respond adequately to ulcer therapy. Routine screening of the upper gastrointestinal tract, without current gastrointestinal symptoms, about to undergo elective surgery for non-upper gastrointestinal disease.

When lower GI endoscopy reveals the cause of symptoms, abnormal signs or laboratory tests e. Exceptions can be considered if medical necessity for this procedure can be demonstrated. GI Procedures Frequently Miscoded When a GI procedure has to be stopped or is not completed because of problems with the scope, irregular patient anatomy, encountering a tumor, or a poor prep, the ASC should append either a Reduced Procedure or the Discontinued Procedure Modifier to the CPT code for the procedure that was terminated.

The choice of modifier would depend on the preference of the payor to whom the claim is being submitted. For either a Colonoscopy or EGD, if the one lesion is biopsied, and a separate lesion is removed during the same case, code both the biopsy of the lesion and the removal of the separate lesion — as long as the lesions are at least one cm.

Append a —59 Modifier to the biopsy procedure, if it is Unbundled from the excision procedure. If an EGD is performed with a biopsy, and then the physician performs an Esophageal Dilation using the scope instrument itself, only the EGD with Biopsy code is billable.

If no Biopsy is performed and the only procedure performed is an Esophageal Dilation using the scope instrument itself, only the Diagnostic EGD code is billable. Use code for a Colonscopy in which Saline is injected to raise a polyp, ink is injected or Tattooing of a lesion is performed. This code is not usually Unbundled from the Biopsy or Polypectomy codes. If the physician attempts — but fails — to remove a polyp by one example, Snare technique, but is successful at removing the polyp via another technique such as Hot Biopsy Forceps only bill the CPT code for the procedure that was successful Use code for colon polyps treated by the Ablation technique, where a polyp is removed using the APC, laser, heat probe, or other device to cauterize it or the remnants of a polyp previously removed during a colonoscopy procedure.

Use this code also when polyps are Fulgurated. Colonoscopy procedures performed through Stomas Ileostomy and Colostomy patients are coded from section codes. C23 Malignant neoplasm of gallbladder. A0 Gastrointestinal stromal tumor, unspecified site.

A1 Gastrointestinal stromal tumor of esophagus. A2 Gastrointestinal stromal tumor of stomach. A9 Gastrointestinal stromal tumor of other sites. A0 Cutaneous T-cell lymphoma, unspecified, unspecified site. A9 Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites. D62 Acute posthemorrhagic anemia. E45 Retarded development following protein-calorie malnutrition.

E46 Unspecified protein-calorie malnutrition. K23 Disorders of esophagus in diseases classified elsewhere. Posted by Lori at Newer Post Older Post Home. Colonoscopy Billing - CPT , Anesthesia services - Gastrointestinal endoscopy - CPT ,

POULTRY RATIONS and Feeding Methods